Table 1 Patient baseline clinical characteristics

N

18

Age

Years

67.5 (48–84)

Sex, male

n (%)

14 (77.8)

Duration of hemodialysis

Years

2.7 (0.3–30)

Etiology of end-stage renal disease

n (%)

 Diabetic nephropathy

9 (50.0)

 Hypertensive kidney disease

5 (27.8)

 Glomerulonephritis

2 (11.1)

 Others

2 (11.1)

Weight

kg

65.5 (46.0–81.5)

HCV genotype

n (%)

 1b

9 (50.0)

 2a

6 (33.3)

 2b

3 (16.7)

HCV treatment history

n (%)

 Naïve

14 (77.8)

 Interferon-based therapy

3 (18.8)

 Interferon-free therapy: daclatasvir and asunaprevir

3 (18.8)

Liver cirrhosis

n (%)

4 (22.2)

Serum HCV-RNA levels

Log₁₀IU/ml

6.55 (4.1–7.3)

Baseline polymorphisms

n (%)

 NS3/4 only

0

 NS5A only

0

 Both NS3 and NS5A

3 (16.7)

 Hemoglobin

g/dL

11.8 (9.9–14.5)

 White blood cell

/μl

5650 (3300–8000)

 Platelets

× 10⁴/μl

17.4 (6.2–27.8)

 Aspartate aminotransferase

IU/L

20 (9–162)

 Alanine aminotransferase

IU/L

16 (5.0–168)

 Total protein

g/dL

7.3 (6.0–8.7)

 Serum albumin

g/dL

4.0 (2.4–4.5)

 Blood urea nitrogen

mg/dL

41.0 (19.9–63.0)

 Creatinine

mg/dL

8.6 (4.4–13.0)

 Total bilirubin

mg/dL

0.4 (0.2–0.9)

 Hemoglobin A1c

%

5.7 (4.3–8.8)

 Alpha-fetoprotein

ng/ml

2.0 (1–4.8)

 M2BPGi

C.O.I

1.9 (0.52–19)